Camurus AB CAMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 648.00
- Day Range
- SEK 636.50–654.50
- 52-Week Range
- SEK 299.80–715.00
- Bid/Ask
- SEK 640.00 / SEK 641.00
- Market Cap
- SEK 37.53 Bil
- Volume/Avg
- 36,172 / 71,275
Key Statistics
- Price/Earnings (Normalized)
- 112.42
- Price/Sales
- 23.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 228
- Website
- https://www.camurus.com
Comparables
Valuation
|
Metric
|
CAMX
|
EGTX
|
FLERIE
|
|---|---|---|---|
Price/Earnings (Normalized) | 112.42 | — | 0.20 |
Price/Book Value | 12.82 | 3.22 | 0.75 |
Price/Sales | 23.46 | 17.80 | 2,238.05 |
Price/Cash Flow | 82.65 | — | — |
Price/Earnings
CAMX
EGTX
FLERIE
Financial Strength
|
Metric
|
CAMX
|
EGTX
|
FLERIE
|
|---|---|---|---|
Quick Ratio | 7.11 | 1.55 | 31.25 |
Current Ratio | 7.41 | 1.56 | 31.25 |
Interest Coverage | 200.63 | −22.42 | −175.65 |
Quick Ratio
CAMX
EGTX
FLERIE
Profitability
|
Metric
|
CAMX
|
EGTX
|
FLERIE
|
|---|---|---|---|
Return on Assets (Normalized) | 14.11% | −49.14% | −10.31% |
Return on Equity (Normalized) | 17.07% | −65.52% | −10.73% |
Return on Invested Capital (Normalized) | 14.74% | −56.41% | −12.52% |
Return on Assets
CAMX
EGTX
FLERIE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mztjgvrdpc | Hxw | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bmcqnhv | Wwcvsps | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Shmtzdgtf | Qvlgy | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Phrfxsvyy | Mbtvlvw | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jymssfvw | Zcrds | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ytqxxckh | Chvsy | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xkxltmd | Vbvv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bzfvmqk | Nxn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cxmgsypxx | Gjwgz | $13.4 Bil | |||
| Incyte Corp
INCY
| Vcjlrkwh | Gnlms | $12.7 Bil |
United States